Bioventus Inc.

BVS Healthcare Medical Devices

Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024.

Revenue
+2.73%
EPS
+100.6%
Free cash flow
−31.4%
Total debt
−28.8%

Quarter to September 2026, against a year earlier

10.68 0.00 0.00%
Market cap
$899.9M
P/E
12.3×
Fwd P/E
17.2×
Dividend yield
—
F-score
8/9
Altman Z
1.26
Beneish M
−2.77
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
7 8 8 8

+8 more TTM periods

ROE
22.96% 22.75% 13.57% 10.98%
ROA
8.33% 7.89% 4.24% 3.22%
ROIC
7.22% 7.34% 7.64% 7.16%
Return on Tangible Assets
44.90% 43.36% 23.15% 16.92%
Average Days of Receivables
86.15 86.82 76.33 82.44
Free Cash Flow per Share
1.24 1.39 1.50 1.08
Free Cash Flow
84.99 94.29 100.63 72.11
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026